[go: up one dir, main page]

UY28894A1 - PIRIMIDINE DERIVATIVES TO TREAT ANOMAL CELL GROWTH - Google Patents

PIRIMIDINE DERIVATIVES TO TREAT ANOMAL CELL GROWTH

Info

Publication number
UY28894A1
UY28894A1 UY28894A UY28894A UY28894A1 UY 28894 A1 UY28894 A1 UY 28894A1 UY 28894 A UY28894 A UY 28894A UY 28894 A UY28894 A UY 28894A UY 28894 A1 UY28894 A1 UY 28894A1
Authority
UY
Uruguay
Prior art keywords
cell growth
anomal
treat
pirimidine derivatives
derivatives
Prior art date
Application number
UY28894A
Other languages
Spanish (es)
Inventor
John Charles Kath
Michael Joseph Luzzio
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34966230&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY28894(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of UY28894A1 publication Critical patent/UY28894A1/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a un compuesto de fórmula 1 en la que R1-R4 son como se definen en esta memoria. Dichos derivados de pirimidina nuevos son útiles en el tratamiento del crecimiento celular anómalo, tal como el cáncer, en mamíferos. Esta invención también se refiere a un método para usar dichos compuestos en el tratamiento del crecimiento celular anómalo en mamíferos, especialmente seres humanos, y a composiciones farmacéuticas que contienen dichos compuestos.The present invention relates to a compound of formula 1 in which R1-R4 are as defined herein. Such novel pyrimidine derivatives are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method for using said compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing said compounds.

UY28894A 2004-05-14 2005-05-12 PIRIMIDINE DERIVATIVES TO TREAT ANOMAL CELL GROWTH UY28894A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US57131204P 2004-05-14 2004-05-14

Publications (1)

Publication Number Publication Date
UY28894A1 true UY28894A1 (en) 2005-12-30

Family

ID=34966230

Family Applications (1)

Application Number Title Priority Date Filing Date
UY28894A UY28894A1 (en) 2004-05-14 2005-05-12 PIRIMIDINE DERIVATIVES TO TREAT ANOMAL CELL GROWTH

Country Status (27)

Country Link
EP (1) EP1751143A1 (en)
JP (1) JP4099212B2 (en)
KR (1) KR100886990B1 (en)
CN (2) CN1953974A (en)
AP (1) AP2241A (en)
AR (1) AR049097A1 (en)
AU (2) AU2005243397A1 (en)
BR (1) BRPI0511138A (en)
CA (1) CA2566707A1 (en)
CR (1) CR8749A (en)
EA (1) EA200601796A1 (en)
EC (1) ECSP066997A (en)
GE (1) GEP20104875B (en)
GT (1) GT200500113A (en)
IL (1) IL178828A0 (en)
MA (1) MA28583B1 (en)
MX (1) MXPA06011890A (en)
NL (2) NL1029045C2 (en)
NO (1) NO20064576L (en)
NZ (1) NZ550448A (en)
PA (1) PA8632601A1 (en)
PE (1) PE20060240A1 (en)
TN (1) TNSN06370A1 (en)
TW (1) TWI303635B (en)
UY (1) UY28894A1 (en)
WO (1) WO2005111023A1 (en)
ZA (1) ZA200608394B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005118544A2 (en) * 2004-05-18 2005-12-15 Rigel Pharmaceuticals, Inc. Cycloalkyl substituted pyrimidinediamine compounds and their uses
US20070032514A1 (en) * 2005-07-01 2007-02-08 Zahn Stephan K 2,4-diamino-pyrimidines as aurora inhibitors
EA014551B1 (en) * 2005-12-21 2010-12-30 Пфайзер Продактс Инк. Pyrimidine derivatives for the treatment of abnormal cell growth
ES2593486T3 (en) * 2007-04-18 2016-12-09 Pfizer Products Inc. Sulfonyl amide derivatives for the treatment of abnormal cell growth
EP2183225A1 (en) * 2007-07-17 2010-05-12 Rigel Pharmaceuticals, Inc. Cyclic amine substituted pyrimidinediamines as pkc inhibitors
JP2011505407A (en) * 2007-12-03 2011-02-24 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Diaminopyridine for treating diseases characterized by excessive or abnormal cell proliferation
WO2009143389A1 (en) * 2008-05-21 2009-11-26 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
US8410126B2 (en) * 2009-05-29 2013-04-02 Boehringer Ingelheim International Gmbh Pyrimidine inhibitors of PKTK2
WO2011018517A1 (en) 2009-08-14 2011-02-17 Boehringer Ingelheim International Gmbh Regioselective preparation of 2-amino-5-trifluoromethylpyrimidine derivatives
US8933227B2 (en) 2009-08-14 2015-01-13 Boehringer Ingelheim International Gmbh Selective synthesis of functionalized pyrimidines
US20120244141A1 (en) 2010-09-28 2012-09-27 Boehringer Ingelheim International Gmbh Stratification of cancer patients for susceptibility to therapy with PTK2 inhibitors
WO2014174745A1 (en) * 2013-04-26 2014-10-30 国立大学法人京都大学 Eg5 INHIBITOR
CN109608444B (en) * 2018-11-27 2022-02-11 中国药科大学 ERK inhibitor containing isoindolinone and preparation method and use thereof
CN111732548B (en) * 2020-06-11 2022-06-17 浙江大学 N2-carbamyl aromatic ring-2-aminopyrimidine derivatives and medical application thereof
WO2024140671A1 (en) * 2022-12-29 2024-07-04 南京昕瑞再生医药科技有限公司 Fused tricyclic derivative, pharmaceutical composition comprising same, and use thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721437D0 (en) * 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
AR042586A1 (en) 2001-02-15 2005-06-29 Sugen Inc 3- (4-AMIDOPIRROL-2-ILMETILIDEN) -2-INDOLINONE AS INHIBITORS OF PROTEIN KINASE; YOUR PHARMACEUTICAL COMPOSITIONS; A METHOD FOR THE MODULATION OF THE CATALYTIC ACTIVITY OF PROTEINQUINASE; A METHOD TO TREAT OR PREVENT AN AFFECTION RELATED TO PROTEINQUINASE
WO2003030909A1 (en) * 2001-09-25 2003-04-17 Bayer Pharmaceuticals Corporation 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
EP1625121B1 (en) * 2002-12-20 2010-02-24 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth

Also Published As

Publication number Publication date
TW200539871A (en) 2005-12-16
IL178828A0 (en) 2007-03-08
AP2241A (en) 2011-06-01
KR100886990B1 (en) 2009-03-04
NL1031845C2 (en) 2006-11-23
NL1029045C2 (en) 2006-06-02
AU2009238255A1 (en) 2009-12-03
NZ550448A (en) 2010-11-26
GT200500113A (en) 2006-01-10
KR20070012477A (en) 2007-01-25
MA28583B1 (en) 2007-05-02
AU2005243397A1 (en) 2005-11-24
WO2005111023A1 (en) 2005-11-24
GEP20104875B (en) 2010-01-11
MXPA06011890A (en) 2006-12-14
AR049097A1 (en) 2006-06-28
PA8632601A1 (en) 2006-06-02
CR8749A (en) 2006-12-05
EA200601796A1 (en) 2007-04-27
NO20064576L (en) 2006-11-07
CN1953974A (en) 2007-04-25
JP2007537234A (en) 2007-12-20
CA2566707A1 (en) 2005-11-24
BRPI0511138A (en) 2007-11-27
ZA200608394B (en) 2008-05-28
AP2006003790A0 (en) 2006-10-31
TWI303635B (en) 2008-12-01
ECSP066997A (en) 2007-02-28
NL1031845A1 (en) 2006-07-31
NL1029045A1 (en) 2005-11-15
CN102127058A (en) 2011-07-20
JP4099212B2 (en) 2008-06-11
PE20060240A1 (en) 2006-04-01
TNSN06370A1 (en) 2008-02-22
EP1751143A1 (en) 2007-02-14

Similar Documents

Publication Publication Date Title
HN2005000212A (en) PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
ECSP066406A (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
CU20090175A7 (en) DERIVATIVES OF SULFONIL AMIDA FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
GT200300296A (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
BRPI0510963A (en) pyrimidine derivatives for the treatment of abnormal cell growth
UY28894A1 (en) PIRIMIDINE DERIVATIVES TO TREAT ANOMAL CELL GROWTH
ECSP078060A (en) 2,4-DIAMINO-PYRIMIDINS AS AURORA INHIBITORS
ECSP088563A (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
BRPI0513310A (en) tetrapeptide analogs
ECSP088210A (en) SUBSTITUTED BENCIMIDAZOLS AND PREPARATION METHODS
ECSP088749A (en) TETRAHYDROPIRIDOTIENOPIRIMIDINE COMPOUNDS AND PROCEDURES FOR THE SAME USE
UY29414A1 (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF HYPERPROLIFERATIVE DISORDERS
PA8592801A1 (en) BICYCLE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
DOP2009000214A (en) ERYTHROMYCIN-BASED MACROLIDS
UY29498A1 (en) AMINO ACID DERIVATIVES
CU23712B7 (en) PIRIMIDINE DERIVATIVES TO TREAT ANOMAL CELL GROWTH
DOP2005000086A (en) PIRIMIDINE DERIVATIVES TO TREAT ANOMALO CELLULAR GROWTH
SV2006002113A (en) PIRIMIDINE DERIVATIVES TO TREAT ANOMAL CELL GROWTH REF. PC32279A
NI200500205A (en) "PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ANORMA CELLULAR GROWTH."
UY28136A1 (en) PIRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELLULAR GROWTH
UA93313C2 (en) Benzimidazole derivatives

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20160617